All Stories

  1. cis-cyclopropylamines as mechanism-based inhibitors of monoamine oxidases
  2. Predicting targets of compounds against neurological diseases using cheminformatic methodology
  3. Correction to Computational Comparison of Imidazoline Association with the I2 Binding Site in Human Monoamine Oxidases
  4. Interdisciplinary Chemical Approaches for Neuropathology
  5. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease
  6. Computational Comparison of Imidazoline Association with the I2 Binding Site in Human Monoamine Oxidases
  7. Live cell interactome of the human voltage dependent anion channel 3 (VDAC3) revealed in HeLa cells by affinity purification tag technique
  8. Inhibitor Design for Monoamine Oxidases
  9. Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
  10. Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
  11. An improved approach to steady-state analysis of monoamine oxidases
  12. Dietary inhibitors of monoamine oxidase A
  13. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B
  14. 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors
  15. TCP-FA4: A derivative of tranylcypromine showing improved blood–brain permeability
  16. Carnitine, mitochondrial function and therapy☆
  17. Characterization of the Covalently Bound Anionic Flavin Radical in Monoamine Oxidase A by Electron Paramagnetic Resonance
  18. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A
  19. Orientation of oxazolidinones in the active site of monoamine oxidase
  20. The G553M Mutant of Peroxisomal Carnitine Octanoyltransferase Catalyses Acetyl Transfer and Acetyl-CoA Hydrolysis
  21. Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines
  22. Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A
  23. Conformational changes in monoamine oxidase A in response to ligand binding or reduction
  24. A snapshot of carnitine acetyltransferase
  25. Interactions of D-amphetamine with the active site of monoamine oxidase-A
  26. Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure
  27. Inhibitors alter the spectrum and redox properties of monoamine oxidase A
  28. Studies on the Characterization of the Inhibitory Mechanism of 4′-Alkylated 1-Methyl-4-Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport Particles
  29. Substrates but Not Inhibitors Alter the Redox Potentials of Monoamine Oxidases
  30. The Role of the Carnitine System in Peroxisomal Fatty Acid Oxidation
  31. A Brief History of Carnitine and its Presence in the CNS
  32. Inhibition of Monoamine Oxidase A by β-Carboline Derivatives
  33. Inhibition of NADH oxidation by 1-methyl-4-phenylpyridinium analogs as the basis for the prediction of the inhibitory potency of novel compounds
  34. Inhibition of NADH oxidation by 1‐methyl‐4‐phenylpyridinium analogs as the basis for the prediction of the inhibitory potency of novel compounds
  35. Syntheses, Structures, and Enzymic Evaluations of Conformationally Constrained, Analog Inhibitors of Carnitine Acetyltransferase: (2R,6R)-, (2S,6S)-, (2R,6S)-, and (2S,6R)-6-(Carboxylatomethyl)-2-(hydroxymethyl)-2,4,4-trimethylmorpholinium
  36. Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies
  37. Chapter 3 Redox properties of the flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism
  38. The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase
  39. Reactivation of NADH Dehydrogenase (Complex I) Inhibited by 1-Methyl-4-(4'-Alkylphenyl)pyridinium Analogues: A Clue to the Nature of the Inhibition Site
  40. Oxidation of tetrahydrostilbazole by monoamine oxidase A demonstrates the effect of alternate pathways in the kinetic mechanism
  41. Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. [Erratum to document cited in CA118(13):119713e]
  42. Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase
  43. (+)-Hemipalmitoylcarnitinium strongly inhibits carnitine palmitoyltransferase-I in intact mitochondria
  44. Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoraductase by rotenone, piericidin A, and MPP+
  45. Syntheses, structures, and enzymatic evaluations of hemiacylcarnitiniums, a new class of carnitine acyltransferase inhibitors
  46. Chapter 6 NADH-ubiquinone oxidoreductase
  47. Kinetic mechanism of monoamine oxidase A
  48. Interaction of 1-Methyl-4-Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase
  49. Mechanism of the neurotoxicity of MPTP
  50. Palmitoyl-L-carnitine, a metabolic intermediate of the fatty acid incorporation pathway in erythrocyte membrane phospholipids
  51. A new class of powerful inhibitors of monoamine oxidase A
  52. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone
  53. Biochemical Reactions Leading to Parkinsonian Symptoms Elicited by MPTP
  54. Oxidation of Analogs of l-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Monoamine Oxidases A and B and the Inhibition of Monoamine Oxidases by the Oxidation Products
  55. In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria
  56. Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria
  57. A case of carnitine palmitoyltransferase II deficiency in human skeletal muscle
  58. Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP)+, the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
  59. Biochemistry Of The Neurotoxic Action Of MPTP And What It May Teach Us About The Etiology Of Idiopathic Parkinsonism
  60. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase
  61. Inhibition of NADH oxidation by pyridine derivatives
  62. Biochemical Events in the Development of Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
  63. Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B
  64. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP
  65. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism
  66. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+
  67. Iron-Sulfur Clusters in Mitochondrial Enzymes
  68. Two Small Peptides from Complex II and Their Role in the Reconstitution of Q Reductase Activity and in the Binding of TTF
  69. Relationship of the oxidation state of the iron sulfur cluster of aconitase to activity and substrate binding
  70. INHIBITORS OF CARNITINE TRANSPORT AND METABOLISM
  71. The Effects of Temperature and Some Inhibitors an the Carnitine Exchange System of Heart Mitochondria
  72. The mechanism of fatty acid uptake by heart mitochondria: An acylcarnitine-carnitine exchange
  73. Selective Modulation of Carnitine Long-chain Acyltransferase Activities